2016 OMB Summer Meeting

365 / 435

Multi Laboratory Test – AOAC First Action Method 2012.22 Ascorbic Acid (Vitamin C) in Infant Formula and
Adult/Pediatric Nutritionals.
RDLS-RD150006 E. Campos Giménez (NRC, Lausanne)
Page 3
CONFIDENTIAL
The contents of this document constitute a trade secret and the intellectual property rights thereto belong to Nestlé S. A., Vevey, Switzerland.
This document may not be reproduced or disclosed to third parties without prior authorisation.
STUDY DESCRIPTION
Study Information
Study Title Vitamin C (ascorbic acid) in Infant Formula and Adult/Pediatric Nutritional
Formula by UHPLC-UV, AOAC First Action 2012.22: Multi-Laboratory Study.
Study
Objective
The objective of the study was to validate the current method (AOAC First
Action 2012.22) by determining its precision figures (repeatability and
reproducibility) through a multi-laboratory testing (MLT). This is mandatory to
finalize the work in progress and go forward to obtain Final Action status.
Study
Director
Esther Campos Giménez
Nestlé Research Center
PO Box 44
CH-1000 Lausanne 26
Switzerland
Phone (direct): +41 21 785 94 29
Fax: +41 21 785 85 53
E-mail:
Study Monitor Liaison with SPIFAN/AOAC (Official Methods Board): Sneh Bandhari
Study
Description
The study was divided in two parts: method set up and qualification of
participants (part 1) and multi-laboratory test participation (part 2).
Part 1: method set up and qualification of participants
Each participating laboratory was asked to analyze two practice samples
using the method provided in the protocol and report the results to the Study
Director within the required timelines (6 weeks after receipt). Results within a
range of expected levels qualified the laboratory for the second part of the
study.
Part 2: Multi-Laboratory Test participation
Each qualified laboratory received twenty samples to be analyzed using the
method provided in the protocol. The laboratory was asked to analyze them
on two different days. Each sample was be assigned to either day 1 or day 2.
The results were submitted to the Study Director for evaluation within the
required timelines (6 weeks after receipt).
Continued on next page
AOAC OMB Meeting Book 337